Business
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass., March 20, 2025--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.
About this update from Revvity, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":784,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/3b049b3de47e0ab1a5eaabbf00309068"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0biihBL1tmmgD1XW1HAXXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3b049b3de47e0ab1a5eaabbf00309068","width":784,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ca2P.TleHUajGHnwIJuWbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1Njg7aD02NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3b049b3de47e0ab1a5eaabbf00309068","width":784,"height":320}},"lazy":false},{"type":"text","content":"New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., March 20, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions.","length":644,"tagName":"p"},{"type":"text","content":"The Generation Study, a research project spearheaded by Genomics England in partnership with the National Health Service, is a landmark national initiative aimed at screening up to 100,000 newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing (WGS) in newborn screening. Proactive genomic screening could help healthcare professionals identify risks for pediatric-onset conditions sooner, enabling earlier interventions and personalized care.","length":519,"tagName":"p"},{"type":"text","content":""It is an honor to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England. Our complete solution and local...